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Abstract
Lung hypoplasia (LH) is a life-threatening congenital abnormality with various causes. It involves vascular bed underdevelopment
with abnormal arterial muscularisation leading to pulmonary hypertension. Because underlying molecular changes are imperfectly
known and sometimes controversial, we determined key factors of angiogenesis along intrauterine development, focusing at the
angiopoietin (ANG)/TIE2 system. Lung specimens from medical terminations of pregnancy (9 to 37wk) were used, including LH due
to congenital diaphragmatic hernia (CDH) or other causes, and non-pulmonary disease samples used as controls. ELISA
determination indicated little ANG1 change during pregnancy and no effect of LH whereas TIE2 declined similarly between 9 and 37
wk in LH and controls. By contrast, ANG2 markedly increased in LH from 24 wk whereas it remained stable in controls. Because
VEGF increased also, this was interpreted as an attempt to overcome vascular underdevelopment. Hypothesizing that its inefficiency
might be due to impaired downstream mechanism, eNOS was determined by semi-quantitative western blot and found to be reduced
about 75 , mostly in the instance of CDH. In conclusion, angiogenesis remains defective in hypoplastic lungs despite reactive%
enhancement of VEGF and ANG2 production, which could be due, at least in part, to insufficient eNOS expression.
Author Keywords Congenital Diaphragmatic Hernia ; Lung Development ; Pulmonary Hypertension ; eNOS
MESH Keywords Angiopoietin-1 ; metabolism ; Angiopoietin-2 ; metabolism ; Female ; Humans ; Hypertension, Pulmonary ; Lung ; abnormalities ; blood supply ; 
embryology ; Neovascularization, Pathologic ; physiopathology ; Nitric Oxide Synthase Type III ; deficiency ; Pregnancy ; Receptor, TIE-2 ; metabolism ; Vascular Endothelial
Growth Factor A ; metabolism
Lung hypoplasia (LH) commonly occurs in association with congenital anomalies, especially congenital diaphragmatic hernia (CDH)
and kidney or urinary tract disorders ( , ). Hypoplastic lungs present marked reduction in the number of bronchial divisions, as well33 43 
as in the development of distal airways. Because vascular development parallels that of airways, underdevelopment of the pulmonary
vascular bed, which is associated with abnormal muscularisation of the arterial walls, is a feature of hypoplastic lungs ( , ). This,20 28 
along with excessive vasoconstrictor mechanisms ( ), leads to pulmonary hypertension at birth ( ). Despite progress in the care of9 6 
newborn infants with LH and pulmonary hypertension, the mortality rate remains elevated. Although vascular abnormalities with
decreased number of vessels per lung volume-unit and increased muscularisation of pulmonary arteries emerged as a determinant of
survival in LH, little information exists with regard to underlying mechanisms. Better understanding the pathophysiology of LH may help
defining novel therapeutic approaches and achieving better outcome.
Only few factors involved in lung vasculogenesis/angiogenesis have been documented in human fetuses or neonates with LH. Indeed,
abnormal expression of sonic hedgehog, hypoxia-inducible factor 1, and vascular endothelial growth factor (VEGF)-A, all known to direct
airway branching and/or distal pulmonary vascular development ( ) was reported in human fetuses with CDH ( , , ). Factors that45 10 34 44 
regulate pulmonary vascular tone during transition of pulmonary circulation at birth have been also partially explored. Higher
concentrations of endothelin-1, considered as a powerful vasoconstrictive mediator, and increased expression of its receptors ETA and
ETB have been found in plasma and pulmonary arteries of newborns with CDH, respectively ( , ). Lastly, previous attempts to9 21 
demonstrate the contribution of nitric oxide synthases (NOS) in LH-induced hypertension have yielded mixed results, with some studies
showing that NOS were decreased at birth ( , ), whereas others showed unaffected expression level of these enzymes ( , ).35 38 10 35 
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In the present study, we focused on the angiopoietin (ANG)/TIE2 system as potential candidate regulators of vascular remodeling in
LH. Vasculogenesis and angiogenesis are mainly regulated by the interplay between VEGF and angiopoietins. ANG1 and 2 bind the
endothelial receptor tyrosine kinase TIE-2. During normal development, ANG1 and TIE2 are required for correct organization and
maturation of newly formed vessels. Mice deficient for these factors die at mid gestation and display dilated vessels, diminished branching,
and reduced number of small vessels ( , ). A similar phenotype was observed in mice overexpressing the Ang2 gene, indicating that13 42 
ANG2 is able to counteract ANG1 activity ( ). A number of studies, however, suggested that ANG2 displays pro-angiogenic properties25 
at high concentration ( ) or in combination with VEGF-A ( , ), revealing the complexity of ANG2 functions. In addition to its role26 24 48 
in vascular development, growing evidence suggests that the ANG/TIE2 pathway influences pulmonary smooth muscle hyperplasia ( , 11 
).12 
Given these considerations, we hypothesized that the hypoplastic lung might present unbalanced expression of angiopoietins, TIE2,
and VEGF, which might in turn contribute to vascular underdevelopment and lung hypertension at birth. We determined the pulmonary
content of these factors in human fetuses with LH of various causes at different developmental stages, comparatively to normal fetal lungs.
This represents the first study of this pathway in human lung in the course of gestational development.
MATERIALS AND METHODS
Human lung tissue
Post mortem lung tissue samples were obtained at autopsy after medical termination of pregnancy or neonatal death Lung tissues were
immediately frozen and stored at 80 C. Terminations were performed according to the July 1994 French legislation, and the study was− °
undertaken with the agreement of the institutional Ethical Committee. Parents were informed about the procedure and issues of post
mortem study, and signed consent was obtained for all included samples. The prenatal diagnosis of CDH, lung hypoplasia, and other
congenital abnormalities was made by ultrasound and was confirmed by post mortem examination. Reduced lung weight and consistent
histological appearance confirmed the diagnosis of pulmonary hypoplasia (lung to body weight ratio <0.015 before 28 wk of pregnancy,
and <0.012 thereafter) . Fetuses were checked for other malformations and for the presence or absence of associated[Table 1 ]
chromosomal abnormality. In the instance of CDH, the lung ipsilateral to the hernia was used. Lungs from fetuses with nonpulmonary
malformations were used as controls; they appeared to be histologically normal by post mortem examination and were not hypoplastic. No
cardiovascular disease was included in the control group. Clinical data are depicted in . Previous studies using those human lungTable 2 
tissue samples had shown preservation of proteins and feasibility of their analysis ( ). Preservation of RNAs was by contrast insufficient5 
and inconsistent, and therefore neither quantitative study at the pre-translational level nor in situ hybridization could be performed. Fetal
age (post conceptional) is used throughout the paper.
Lung histology and vascular immunohistochemistry
Because of restrictions in human tissue sampling conditions, it was not possible to proceed to lung fixation at constant pressure, and
therefore to perform morphometry. Pieces of human lung tissue were fixed in formalin 24h after death. Fixed tissues were
paraffin-embedded. Five- m sections were dehydrated in xylene and graded ethanol, and then stained with orcein-picroindigo-carmine.μ
Immunohistochemistry of platelet endothelial cell adhesion molecule-1 (PECAM-1) was performed using the biotin/streptavidin RTU
Vectastain Universal Quick kit (Vector laboratories, Burlingame, CA), according to the manufacturer s instructions. Briefly, the slides’
were dewaxed and rehydrated in graded ethanol solutions. Endogenous peroxidases were quenched by incubating the slides in
methanol/0.3  H O at room temperature for 30 min. Antigen retrieval was performed by microwave heating in citrate buffer solution% 2 2 
(pH 6.0). Sections were then blocked in PBS containing 1.5  normal horse serum for 1 hour at room temperature, probed with monoclonal%
mouse anti-human PECAM-1 antibody (diluted 1:50, clone: JC/70A, DAKO, Carpintera, CA) overnight at 4 C, and incubated with°
prediluted biotinylated panspecific IgG for 10 minutes. Lung sections serving as negative controls received the same dilution of
non-immune mouse IgG. The slides were incubated with HRP-conjugated streptavidin for 5 minutes. NovaRED (Vector Laboratories) was
used as substrate. After counterstaining with hematoxylin, tissue sections were dehydrated and mounted. Light microscopy images were
captured with a digital camera.
Western blot
Human lung tissue was homogenized in RIPA buffer containing protease inhibitors (Roche Diagnostics, Meylan, France). Protein
content was assessed with Bradford assay. Sixty micrograms of total proteins were electrophoresed on 7.5  SDS-poplyacrylamide gels%
then transferred onto polyvinylidene-fluoride membrane (Millipore, Velizy, France). To document equivalent protein loading, membranes
were stained with Ponceau S dye (Sigma, Saint-Quentin Fallavier, France) and photographed prior to antibody incubations. After blocking
with 5  nonfat dry milk in Tris-buffer saline containing 0.05  Tween-20 (TTBS) at room temperature for 2h, membranes were exposed% %
to rabbit anti-eNOS (Santa Cruz Biotechnology, Santa Cruz, CA) antibody, washed in TTBS, and exposed to horseradish
peroxidase-conjugated goat anti-rabbit IgG antibody (Santa Cruz Biotechnology) and incubated in enhanced chemiluminescence reagent
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(GE Healthcare Life Sciences, Saclay, France) before exposure to Kodak BioMax MS film. Signals were quantified by densitometry (NIH
Image, Betehesda, MD).
Quantitative assays for VEGF, ANG1, aANG2, and TIE2
VEGF-A , Angiopoietin-1 and -2, and TIE2 concentrations in human fetal lung tissue were assessed with commercially sensitive165 
and specific ELISA (R&D Systems, Lille, France), following the manufacturer s instructions, and normalized to total proteins. The intra’
and inter-assay coefficients of variance were less than 5  for each essay.%
Stastistical analysis
Relationships between ANG1, ANG2, TIE2, and VEGF-A concentrations and fetal age were analyzed using linear regression165 
models, including main effects and interaction terms to compare concentrations between groups. Sensitivity analyses were performed
when outliers were present. Analyses were performed using R statistical software. For eNOS data, multiple group comparisons were made
using Kruskal-Wallis test, and two-group comparisons were made using the Mann-Whitney U-test. A p-value of 0.05 was considered to be
the limit of statistical significance.
Results
Comparative histology and PECAM-1 immunohistochemistry
Control lungs aged 32 33 weeks (fetal age, late saccular stage) displayed large-sized, simple airspaces, relatively wide septa, and focal–
early secondary crest formation, characteristic of late saccular stage of lung development. Although displaying variable morphology,
hypolastic lungs of same age appeared immature with thicker septa, denser tissue, and characteristic thickening of blood vessel walls (Fig.
). In accordance with histological findings, immunostaining of the endothelial-cell marker PECAM-1 (CD31) in control lungs1A C –
demonstrated abundant microvascular structures within the septa, both subepithelially and centrally ( ). By contrast, lungs ofFig. 2A 
fetuses with LH displayed defective vascular development with fewer capillaries less evenly distributed and embedded in a thicker
mesenchyme ( ).Fig. 2B,C 
Lung contents in ANG1, ANG2, and TIE2
The concentration of ANG1, ANG2 and TIE2 proteins was determined in lung tissue samples from 69 fetuses with or without LH
ranging from 9 to 37 wk of pregnancy. As already observed for other parameters in similar samples, ( ) the values were largely dispersed5 
with some overlap between groups. This seems to be inherent of this type of approach with human samples, but did not prevent from
evidencing strongly significant differences between groups. In control and LH lungs, ANG1 concentration did not change significantly
during pregnancy and displayed a mean level of 200 250 pg/mg protein (LH slope vs Control slope: p  0.154, ). Whereas ANG2– = Fig. 3A 
concentration remained similarly unchanged throughout pregnancy in control lungs with a mean level of 750 1000 pg/mg, a marked–
increase was observed in LH lungs (LH slope vs Control slope: p  0.00154, ). In the latter group, ANG2 increased linearly to= Fig. 3B 
reach approximately 3000 4000 pg/mg protein at the later stages. Over the studied period, TIE2 concentration displayed similar profiles in–
control and LH fetuses, slightly decreasing from 9 to 37 wk; no statistical difference was observed between groups, either considering
CDH and other causes separately or altogether (LH slope vs Control slope: p 0.79, ).= Fig. 3C 
Lung contents in VEGF
Given the fact that ANG2 has been shown to have a dual role in angiogenesis depending on the availability of VEGF-A, VEGF-A
concentration was determined during pregnancy in human fetuses with or without pulmonary hypoplasia. Various VEGF-A isoforms are
present in the developing lung. Because (i) temporal and spatial regulation of VEGF-A controls vascular patterning in the embryonic lung
( ) whereas VEGF-C and D are mainly considered to be lymphangiogenic, (ii) defective pulmonary vascular development in mice was2 
consecutive to the loss of both VEGF (termed VEGF in humans) and 188 isoforms ( ), and (iii) transgenic mice expressing only the164 165 14 
VEGF isoform are indistinguishable from the wild type ( ), the 164/165 isoform appears to have an irreplaceable role and was164 39 
therefore studied herein. Similar to ANG2, we found elevated VEGF-A expression level in fetuses with lung hypoplasia (LH slope vs165 
Control slope: p 0.02, ). Considering separately CDH and other causes, the difference between fetuses with LH due to other causes= Fig 4 
(designated LHo) and controls remained statistically significant (p 0.0235), whereas that for the CDH group did not (p 0.077), although= =
very high VEGF-A level was present in some CDH specimens.165 
eNOS protein evaluation in human fetal lungs
eNOS is known to mediate biological effects of both VEGF-A and Angiopoietins ( , , ). Comparatively to mice devoid of the1 3 47 
other isoforms (i.e. inducible NOS and neuronal NOS), the lung phenotype of eNOS mice is the most severe with abnormal lung/  − −
development as well as elevated pulmonary arterial pressure in adulthood ( , ). For these reasons, eNOS expression was evaluated16 38 
semi-quantitatively by western blot in lung tissue samples from fetuses with LH either induced by CDH or other causes and compared to
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age-matched controls. In lungs at the canalicular stage (i.e. 22 25 wk), eNOS protein level was significantly diminished to 25 (p<0.01) and–
45  (p<0.05) of control level in CDH and LHo groups respectively ( ). During saccular stage (i.e. 31 33 wk), eNOS content was% Figure 5 –
reduced to 30  of control level in the CDH group (p<0.05), but not significantly changed in the LHo group. Because of the restricted%
number of specimen available at the alveolar stage, no statistical comparison could be made. However, as shown in , pulmonaryFigure 5C 
eNOS level was markedly reduced in one fetus with CDH compared to two age-matched controls.
Discussion
Successful adaptation of the newborn to extrauterine life depends upon the ability of the pulmonary circulation to undergo rapid fall in
vascular resistance within the first minutes after birth. This critical step follows a lengthy series of highly orchestrated events that
characterize normal growth and maturation of the fetal pulmonary circulation. Since the ANG/Tie2 system plays a crucial role in the
control of vascular development in normal angiogenesis and has been found to be disordered in pathological conditions, we speculated that
abnormal balance in the ANG/Tie2 system might account for the structural vascular abnormalities seen in human fetuses with lung
hypoplasia. We found that the latter is associated with elevated concentration of pulmonary ANG2 during the second half of pregnancy.
Although controversial, the implication of the ANG1-Tie2 pathway in the pathogenesis of pulmonary arterial hypertension has been
the object of numerous investigations ( , , ). By contrast, the role of the ANG/Tie2 system during lung development has been only11 12 22 
partially explored. Hato T et al. ( ) recently reported that mice expressing a potent Ang1 variant under the control of a lung-specific17 
promoter displayed blood vessel enlargement and 50  lethality at birth due to respiratory failure, indicating that a precise regulation of%
Tie2 signaling through angiopoietin control is required for harmonious lung vascular network formation. Previous descriptive studies
suggested that ANG2 is a complex regulator of vascular remodeling that may play antagonistic roles in both vessel sprouting and vessel
regression, depending on the availability of VEGF-A. Supporting such roles, expression analyses revealed that ANG2 is rapidly induced in
the absence of VEGF-A in settings of vascular regression ( ), whereas ANG2 is induced together with VEGF-A in settings of angiogenic15 
sprouting ( , ). In the latter instance, it has been proposed that ANG2 makes mature vessels unstable by blocking the effects of18 41 
ANG1. This ANG2-mediated destabilization is thought to facilitate access to other classes of angiogenic factors such as VEGF-A. To try
clarifying the pathophysiological significance of ANG2 elevation in fetuses with LH, we therefore explored VEGF-A protein level. In165 
agreement with a previous report that VEGF immunoreactivity was increased in the endothelium and medial smooth muscles cells of
pulmonary arteries in newborns with CDH and pulmonary hypertension ( ), we found enhanced VEGF-A expression in lung tissue34 165 
from fetuses with LH compared to controls during the second half of pregnancy. Consequently, we speculate that concomitant increases in
ANG2 and VEGF-A may reflect an attempt of the hypoplastic lung to overcome vascular underdevelopment. Considering the165 
persistence of impaired angiogenesis illustrated by decreased lung-vessel density observed in previous post mortem studies ( , ) as10 20 
well as in the present study, this appears to be inefficient, which suggests abnormal function of effectors. To test this hypothesis, attention
was paid to eNOS that we found to be decreased in fetuses with LH, especially in the instance of the one associated with CDH. Using
immunohistochemistry, a previous study had evidenced no difference in pulmonary eNOS expression between fetuses with LH and
age-matched controls ( ). A possible explanation for the discrepancy between this and our investigation is the lack of sensitivity of10 
immunohistochemistry to quantitatively appreciate expression changes, whereas western blotting that we used allows semi-quantitative
comparison to be performed. Our finding of reduced eNOS expression in human fetuses with LH is by contrast consistent with that from
another investigation conducted on arteries of newborns with CDH complicated by persistent pulmonary hypertension in which eNOS
expression level was found to be decreased ( ). Moreover, in the present study, we demonstrated that eNOS reduction occurs early in the38 
course of pathological lung development. A marked reduction in hypoplastic lungs was thus observed at the canalicular stage during which
intracinar capillaries develop, and was likely to be still present at saccular and alveolar stages. Interestingly, mice devoid of eNOS exhibit
major defects in lung morphogenesis with a lung phenotype that closely mimics histological features of alveolar capillary dysplasia (ACD)
( ). CDH and ACD are both characterized by decreased number of alveolar units, medial thickening of small pulmonary arteries with16 
muscularization of arterioles, and thickened interalveolar septa ( ). Newborns with PPHN secondary to CDH or ACD are often37 
refractory to inhaled NO ( ). In addition treatment of lung explants with nitro-L-arginine, a NOS inhibitor, led to a significant loss in19 
branching morphogenesis ( ) and a failure of compensatory lung growth following pneumonectomy has been demonstrated in eNOS27 
knockout mice ( ). Taken together, these data provide direct evidence that substantial alterations in NO production not only contribute to23 
dysregulation of vascular tone at birth, but also disturb the molecular and cellular mechanisms that mediate the cross talk between
epithelium and mesenchyme to coordinate airway and vessel development during lung development.
The mechanism leading to eNOS decrease is not clear. Since physical forces regulate eNOS mRNA expression and play a crucial role
in lung growth, prolonged mechanical restriction due to inadequate amniotic fluid production and/or lung compression by viscera could be
responsible for the low levels of eNOS observed in fetuses with lung hypoplasia.
Rodent and lamb models have been developed and extensively used to explore the physiopathology of human CDH and to test the
safety and efficacy of new therapies. Numerous opposite results have been reported in both inter- and intra-animal models, especially
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regarding surfactant status and vascular development, underlying the inherent limitations of animal models. For instance, Oue et al. ( )31 
showed that VEGF mRNA as well as protein levels were significantly increased in lungs of nitrofen-treated rats, whereas two other studies
( , ) reported diminished VEGF expression in the same model. Similar discrepancies were found for eNOS ( , ).7 8 29 30 
This study however presents some limitations that must be considered. Firstly, and despite the fact that specimens were processed in
the same way, histological investigations were performed on small lung tissue samples obtained at autopsy and fixed after sample removal,
a procedure known to influence histological interpretation. Next, the relatively small number of fetuses examined, especially at the
alveolar stage, may have contributed to reduce the power of the study. Investigation on a larger population is therefore desirable to confirm
the present findings. Finally, the mechanism leading to, and the biological significance of ANG2 and VEGF upregulation in fetuses with
LH are uncertain. It must be underlined that the increase of ANG2 expression during pregnancy may counteract the specific
vessel-stabilizing effects of ANG1, or mediate deleterious effects, as reported in the instances of bronchopulmonary dysplasia ( ) or of4 
acute septic lung injury ( ).32 
Collectively, our results nonetheless document further the abnormal vascular development associated with LH. Enhancing pulmonary
eNOS appears as a therapeutic objective in this condition. This is further supported by the finding that NO-donor promoted branching
morphogenesis in control and nitrofen-exposed fetal lung explants ( , , ).27 36 46 
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Figure 1
Representative histological sections of fetal human lungs aged 32 33 weeks (fetal age) without (A, control lung) or with (B, CDH, and C,–
urogenital defect) lung hypoplasia (LH). Tissue was stained by orcein-picroindigo-carmine. All pictures are at same magnification. Structure
of hypoplastic lungs appears immature with dense parenchyma, thicker septa, and reduced presumptive airspaces. Note thickening of
blood-vessel walls in B and C.
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Figure 2
Immunostaining of platelet endothelial cell adhesion molecule-1 (PECAM-1). Lung sections from fetuses aged 32 33 weeks (fetal age)–
without (A, control lung) or with (B, CDH, and C, urogenital defect) LH were immunostained with mouse monoclonal anti-human PECAM-1
antibody and counterstained with hematoxylin. All pictures are at same magnification. Control fetuses had extensive staining of endothelial
cells within septa, whereas immunostaining appeared less intense in the hypoplastic lungs that displayed reduced complex intertwining of
alveolar capillaries.
Figure 3
Scatter plots of ANG1, ANG2, and TIE2 concentrations (pg/mg protein) in human lung fetuses as a function of fetal age (wk). Individual
values are shown: open, black, and grey points correspond to control fetuses, fetuses with pulmonary hypoplasia due to CDH, and fetuses with
pulmonary hypoplasia due to other causes, respectively. Solid line represents the regression line of control fetuses, hatched line represents the
regression line of fetuses with lung hypoplasia (either cause). Two extreme ANG1, ANG2, and TIE2 outliers were discarded for calculating
scatters plots. Difference between control and LH fetuses (CDH  other causes) was significant only for Ang2 that was increased in late+
gestation (LH slope vs Control slope: p  0.00154). Clinical data of fetuses are depicted in and .= Tables 1 2 
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Figure 4
Scatter plot of VEGF concentration (pg/mg protein) in human lung fetuses as a function of fetal age (wk). Individual values are shown:165 
open, black, and grey points correspond to control fetuses, fetuses with pulmonary hypoplasia due to CDH, and fetuses with pulmonary
hypoplasia due to other causes, respectively. Solid line represents the regression line of control fetuses, hatched line represents the regression
line of fetuses with lung hypoplasia (either cause). VEGF was markedly increased in hypoplastic lungs in late gestation (LH vs controls165 
slope: p 0.02).=
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Figure 5
eNOS protein level as a function of developmental stages in human lung fetuses with or without pulmonary hypoplasia. Canalicular stage: (A)
representative western blots in CDH, lung hypoplasia due to other causes (LHo), and control lungs; (B) corresponding densitometric analysis
normalized by Ponceau. Saccular and alveolar stages: (C) representative western blots; (D) densitometric analysis for saccular stage
normalized by Ponceau S. Signal for eNOS protein was evidenced at 135 kDa (B and D). Results are expressed as percentage of control-group
mean value. Box plot: the boundary of the box indicates the 25th and 75th percentiles, the bold line and the cross within the box mark the
median and mean values, respectively, and whiskers represent minimum and maximum values. eNOS protein was significantly diminished in
CDH and LHo groups at the canalicular stage, and in CDH group at the saccular stage (significant difference with respective control group
for: (a) p<0.05; (b) p<0.01).
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Table 1
Characteristics of Fetuses with Pulmonary Hypoplasia
Number Fetal Age (weeks) Sex Syndrome Body Weight (g) Lung Weight-to-Body Weight Ratio
1 13 M CDH, left 62 0.015
2 21 F CDH, right 550 0.01
3 22 F CDH, right 610 0.008
4 22 F CDH, right 780 0.008
5 22 M CDH 500 0.005
6 22 F CDH, left 660 0.008
7 22 ND CDH ND ND
8 23 F CDH, left 850 0.015
9 23 M CDH 730 0.009
10 23 M CDH 780 0.006
11 23 M CDH, left 970 0.011
12 25 M CDH, left 1270 0.008
13 29 M CDH, left 1480 0.0117
14 31 F CDH, left 1900 0.004
15 32 F CDH, left 1960 0.006
16 33 F CDH, left 2200 0.012
17 36 F CDH, left 2340 0.0043
18 36 F CDH, left 2800 0.018
19 37 F CDH, right 3350 0.005
20 37 ND CDH 3852 0.012
21 17 M Hydrothorax 408 0.008
22 18 M Renal anomaly 225 0.019
23 19 M Anamnios 320 0.013
24 23 M Anamnios, multicystic kidney 580 0.012
25 23 M Premature rupture of membranes 890 0.012
26 23 M Multicystic kidney 1160 0.011
27 24 M Multicystic kidney 930 0.0113
28 24 M Posterior urethral valves 880 0.013
29 25 M Anamnios 800 0.015
30 26 M Renal dysplasia 1070 0.014
31 31 F Polymalformation 1580 0.006
32 32 M Anamnios, Multicystic kidney 2460 0.01
33 32 F Akinesia 1620 0.009
34 33 M Hydrothorax 3080 0.007
ND: not determined.
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Table 2
Characteristics of Fetuses with non-pulmonary Diseases Used as Controls
Number Fetal Age (weeks) Sex Syndrome Body Weight (g) Lung Weight-to-Body Weight Ratio
35 9 M Brachio-oto-renal syndrome 3.3 ND
36 11 F Cystic Hygroma 19.2 ND
37 12 F Inencephaly 16 0.037
38 14 M Cloacal defect 150 0.024
39 15 M Hydrops 87 0.013
40 16 F Brain anomaly 173 0.046
41 16 F Thanatophoric dwarfism 143 0.026
42 18 M Spina bifida 253 0.031
43 21 M Omphalocele 530 0.022
44 21 M Osteogenesis imperfecta 510 0.023
45 23 M Holoprosencephaly 800 0.025
46 23 F Brain anomaly 795 0.017
47 23 M Hydrops 1100 0.021
48 23 M In utero death 810 0.019
49 24 M Limb 940 0.027
50 24 M Ectrodactily 760 0.0255
51 24 M Brain anomaly 790 0.024
52 25 M Limb 1050 0.027
53 25 M Brain anomaly 900 0.024
54 26 F Arthrogriposis 1100 0.017
55 27 M Brain anomaly 420 0.072
56 28 M Brain anomaly 1430 0.023
57 29 F Brain anomaly 1400 0.026
58 30 F Bourneville disease 1700 0.0205
59 30 M Brain anomaly 1780 0.023
60 31 M Osteochondrodysplasia 1400 0.016
61 31 F Brain anomaly 2300 0.016
62 33 M Distal arthrogryposis 2560 0.016
63 33 M Trisomy 21 2450 0.026
64 34 M Brain anomaly 2450 0.023
65 35 F Hydrocephaly 2500 0.018
66 35 M Chondrodysplasia 3170 0.0157
67 36 F Holoprosencephaly 1600 0.021
68 36 F Holoprosencephaly 1800 0.022
69 37 F Spina Bifida 3140 0.017
